Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384352 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT06384352: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co..
NCT06384352 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 155 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06384352, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. Part 3 is dose-expansion part. In this part, we will further evaluate the safety and efficacy of YL211 at the MTD/RED(s) in patients with selected advanced solid tumors YL211 will be administered intravenously (IV) until criteria of treatment discontinuation are met.
Primary Outcome
AE's
Conditions Studied
Interventions
- DRUG YL211
Study Locations (20)
Texas
- The University of Texas - MD Anderson Cancer Center - Houston
- NEXT Oncology - Houston - Houston
- NEXT Oncology - Dallas - Irving
- NEXT San Antonio - San Antonio
Other
- Monash Health - Melbourne
- The Ottawa Hospital - General Campus - Ottawa
- West China Hospital, Sichuan University - Chengdu
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
- Sarah Cannon Research Institute (SCRI) at HealthONE - Denver
Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
- Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office - Sarasota
Zhejiang
- The First Affiliated Hospital - Zhejiang University School of Medicine - Hangzhou
- Wenzhou Medical University - The First Affiliated Hospital - Wenzhou
Connecticut
- Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven - North Haven
Nevada
- Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley - Las Vegas
Ohio
- University of Cincinnati Vontz Center for Molecular Studies - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2029-04-07 |
| Phase | Phase 1 |
What NCT06384352 shows while recruiting
NCT06384352 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which YL211 is the first listed.
NCT06384352 names 20 study sites across 12 states, led by Texas, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT06384352 about?
NCT06384352 is a clinical study titled "A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors". This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and R...
What is the current status of trial NCT06384352?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2024-05-01. Estimated completion is 2029-04-07.
What conditions does trial NCT06384352 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06384352?
The interventions under investigation include: YL211 (DRUG).
Who is sponsoring clinical trial NCT06384352?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06384352 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Florida, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06384352's enrollment target sits among peer trials
155 56th of 144 higher than 88 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI